CR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived growth factor-D (PDGF-D), a target shown to play a role in kidney inflammation. This is a novel therapeutic approach to treat kidney inflammation.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of CR002. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of CR002. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of CR002. |
| Estrone | Estrone may increase the thrombogenic activities of CR002. |
| Estradiol | Estradiol may increase the thrombogenic activities of CR002. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of CR002. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of CR002. |
| Mestranol | Mestranol may increase the thrombogenic activities of CR002. |
| Estriol | Estriol may increase the thrombogenic activities of CR002. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of CR002. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of CR002. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of CR002. |
| Tibolone | Tibolone may increase the thrombogenic activities of CR002. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of CR002. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of CR002. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of CR002. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of CR002. |
| Zeranol | Zeranol may increase the thrombogenic activities of CR002. |
| Equol | Equol may increase the thrombogenic activities of CR002. |
| Promestriene | Promestriene may increase the thrombogenic activities of CR002. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of CR002. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of CR002. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of CR002. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of CR002. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of CR002. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of CR002. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of CR002. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of CR002. |
| Formononetin | Formononetin may increase the thrombogenic activities of CR002. |
| Estetrol | Estetrol may increase the thrombogenic activities of CR002. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with CR002. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with CR002. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with CR002. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with CR002. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with CR002. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with CR002. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with CR002. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with CR002. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with CR002. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with CR002. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with CR002. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with CR002. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with CR002. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with CR002. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with CR002. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with CR002. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with CR002. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with CR002. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with CR002. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with CR002. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with CR002. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with CR002. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with CR002. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with CR002. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with CR002. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with CR002. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with CR002. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with CR002. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with CR002. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with CR002. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with CR002. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with CR002. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with CR002. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with CR002. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with CR002. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with CR002. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with CR002. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with CR002. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with CR002. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when CR002 is combined with Rozrolimupab. |
| Girentuximab | The risk or severity of adverse effects can be increased when CR002 is combined with Girentuximab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when CR002 is combined with Obiltoxaximab. |
| XTL-001 | The risk or severity of adverse effects can be increased when CR002 is combined with XTL-001. |
| NAV 1800 | The risk or severity of adverse effects can be increased when CR002 is combined with NAV 1800. |
| Briakinumab | The risk or severity of adverse effects can be increased when CR002 is combined with Briakinumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when CR002 is combined with Otelixizumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when CR002 is combined with AMG 108. |
| Iratumumab | The risk or severity of adverse effects can be increased when CR002 is combined with Iratumumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when CR002 is combined with Enokizumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when CR002 is combined with Ramucirumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when CR002 is combined with Farletuzumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when CR002 is combined with Veltuzumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when CR002 is combined with Ustekinumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when CR002 is combined with Trastuzumab emtansine. |
| PRO-542 | The risk or severity of adverse effects can be increased when CR002 is combined with PRO-542. |
| TNX-901 | The risk or severity of adverse effects can be increased when CR002 is combined with TNX-901. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when CR002 is combined with Inotuzumab ozogamicin. |
| RI 624 | The risk or severity of adverse effects can be increased when CR002 is combined with RI 624. |
| Stamulumab | The risk or severity of adverse effects can be increased when CR002 is combined with MYO-029. |
| CT-011 | The risk or severity of adverse effects can be increased when CR002 is combined with CT-011. |
| Leronlimab | The risk or severity of adverse effects can be increased when CR002 is combined with Leronlimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when CR002 is combined with Glembatumumab vedotin. |
| Olaratumab | The risk or severity of adverse effects can be increased when CR002 is combined with Olaratumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when CR002 is combined with IPH 2101. |
| TB-402 | The risk or severity of adverse effects can be increased when CR002 is combined with TB-402. |
| Caplacizumab | The risk or severity of adverse effects can be increased when CR002 is combined with Caplacizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when CR002 is combined with IMC-1C11. |
| Eldelumab | The risk or severity of adverse effects can be increased when CR002 is combined with Eldelumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when CR002 is combined with Lumiliximab. |
| Canakinumab | The risk or severity of adverse effects can be increased when CR002 is combined with Canakinumab. |